Longevity Health Holdings Inc (XAGE)

Longevity Health Holdings Inc. is a healthcare company focused on bio-aesthetics, with activities centered on the development, manufacturing, and marketing of cosmetic skincare and haircare products. Its product work includes Carmell Secretome and Elevai Exosomes, which are designed to support skin and hair health through ingredients such as growth factors, proteins, peptides, cytokines, and other small molecules associated with the body’s natural healing processes. The company also develops a microemulsion formulation intended to deliver both lipophilic and hydrophilic ingredients without using a group of 14 excipients commonly found in cosmetic products. In addition, Longevity Health Holdings has a licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. Formerly known as Carmell Corporation, the company adopted its current name in March 2025 and is headquartered in Pittsburgh, Pennsylvania. It was founded in 2008 and trades as common stock on OTC Markets under the symbol XAGE.


Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-XAGE
$0.35
54.9% Upside
Bargain
Weak
0.0%
August 14, 2026
-0.1x
-0.1x
0.3x
556.947 K
644.166 K
41.8%
67.3%
-84.2
45.0%
Valuation • Fair Value

Longevity Health Holdings Inc (OTC-XAGE) Fair Value by Valuation Model

Compare the primary fair value estimate for Longevity Health Holdings Inc (OTC-XAGE) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.35

Estimated upside of 54.9% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$0.35

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Longevity Health Holdings Inc (OTC-XAGE) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Longevity Health Holdings Inc (OTC-XAGE)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

1.794 M

Current operating scale indicator.

Revenue Forecast

3.347 M

Forward revenue estimate.

EBITDA

-6.707 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Longevity Health Holdings Inc (OTC-XAGE) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Longevity Health Holdings Inc (OTC-XAGE)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-12.32

No elevated caution signal from this screen.

Altman Z-Score

-84.2

Lower score that deserves closer risk review.

FCF / Net Income

45.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Longevity Health Holdings Inc (OTC-XAGE). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Longevity Health Holdings Inc (OTC-XAGE)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 14, 2026

Days to Earnings

24

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Longevity Health Holdings Inc (OTC-XAGE), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Longevity Health Holdings Inc (OTC-XAGE) Stock Forecast & Technical Outlook

Review Longevity Health Holdings Inc (OTC-XAGE) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Longevity Health Holdings Inc (OTC-XAGE) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Longevity Health Holdings Inc (OTC-XAGE) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Longevity Health Holdings Inc (OTC-XAGE) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Longevity Health Holdings Inc (OTC-XAGE) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Longevity Health Holdings Inc (OTC-XAGE) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Longevity Health Holdings Inc (OTC-XAGE)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Longevity Health Holdings Inc (OTC-XAGE) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ Fast Investor Answers

Longevity Health Holdings Inc (OTC-XAGE) Stock FAQ

Quick answers about Longevity Health Holdings Inc (OTC-XAGE) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.35
Estimated upside 54.9%
Valuation Rating
Undervalued
Estimated upside of 54.9%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for Longevity Health Holdings Inc (OTC-XAGE) is $0.35. This implies an estimated upside of 54.9% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 54.9% versus the current market price.

An analyst price target for Longevity Health Holdings Inc (OTC-XAGE) is not currently available in the latest data file.

The current financial health read for Longevity Health Holdings Inc (OTC-XAGE) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Longevity Health Holdings Inc (OTC-XAGE) is August 14, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Longevity Health Holdings Inc (OTC-XAGE) is -0.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Longevity Health Holdings Inc is 556.947 K.

The current enterprise value listed for Longevity Health Holdings Inc is 644.166 K. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Longevity Health Holdings Inc is OTC-XAGE, and the stock is listed on OTC Markets.

Longevity Health Holdings Inc (OTC-XAGE) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Longevity Health Holdings Inc is 41.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Longevity Health Holdings Inc is 67.3%. Free float helps investors understand how much of the share base is available for public trading.